DK0765357T3 - Antivirale dendrimerer - Google Patents

Antivirale dendrimerer

Info

Publication number
DK0765357T3
DK0765357T3 DK95921661T DK95921661T DK0765357T3 DK 0765357 T3 DK0765357 T3 DK 0765357T3 DK 95921661 T DK95921661 T DK 95921661T DK 95921661 T DK95921661 T DK 95921661T DK 0765357 T3 DK0765357 T3 DK 0765357T3
Authority
DK
Denmark
Prior art keywords
dendrimer
terminal groups
antiviral
dendrimers
antiviral dendrimers
Prior art date
Application number
DK95921661T
Other languages
Danish (da)
English (en)
Inventor
Barry Ross Matthews
George Holan
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Application granted granted Critical
Publication of DK0765357T3 publication Critical patent/DK0765357T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/795Polymers containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595Polyamides, e.g. nylon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/16Dendrimers and dendritic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95921661T 1994-06-15 1995-06-15 Antivirale dendrimerer DK0765357T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM6239A AUPM623994A0 (en) 1994-06-15 1994-06-15 Antiviral dendrimers

Publications (1)

Publication Number Publication Date
DK0765357T3 true DK0765357T3 (da) 2006-07-17

Family

ID=3780809

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95921661T DK0765357T3 (da) 1994-06-15 1995-06-15 Antivirale dendrimerer

Country Status (15)

Country Link
US (1) US6190650B1 (de)
EP (1) EP0765357B9 (de)
JP (2) JPH10501568A (de)
KR (1) KR100365028B1 (de)
CN (1) CN1134486C (de)
AT (1) ATE312866T1 (de)
AU (1) AUPM623994A0 (de)
BR (1) BR9508031A (de)
CA (1) CA2192446C (de)
DE (1) DE69534686T2 (de)
DK (1) DK0765357T3 (de)
ES (1) ES2255060T3 (de)
NZ (1) NZ287819A (de)
PT (1) PT765357E (de)
WO (1) WO1995034595A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
US5795582A (en) * 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
AUPO104396A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
DE19726340C2 (de) * 1996-08-16 1999-05-06 Schering Ag Zinndendrimere, ihre Verwendung als Röntgenkontrastmittel und Verfahren zu ihrer Herstellung
US6719988B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Antiseptic compositions for inactivating prions
US20060008494A1 (en) * 1997-02-21 2006-01-12 The Regents Of The University Of California Complete inactivation of infectious proteins
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
US6331296B1 (en) * 1999-06-01 2001-12-18 Stanley B. Prusiner Food additives which affect conformationally altered proteins
FR2761691B1 (fr) * 1997-04-03 1999-05-14 Oreal Polymeres a fonction terminale thiol
FR2772770B1 (fr) * 1997-12-19 2000-01-28 Oreal Nouveaux composes choisis parmi les polymeres hyperbranches et les dendrimeres ayant un groupement particulier, procede de preparation, utilisation et compositions les comprenant
FR2772771B1 (fr) * 1997-12-19 2000-01-28 Oreal Utilisation de polymeres hyperbranches et de dendrimeres comportant un groupement particulier, en tant qu'agent filmogene, les compositions filmogenes les comprenant et leur utilisation notamment en cosmetique ou en pharmacie
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
EP1609467A1 (de) * 1998-07-28 2005-12-28 Neurochem (International) Limited Zusammensetzungen zur Behandlung von mit Glykosaminoglykan-zusammenhängenden molekularen Wechselwirkungen verbundenen Erkrankungen
AU767971B2 (en) * 1998-09-14 2003-11-27 Starpharma Pty Limited Inhibition of toxic materials or substances using dendrimers
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
US7572459B2 (en) 1998-09-14 2009-08-11 Starpharma Pty Ltd. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
AU767970B2 (en) * 1998-09-14 2003-11-27 Starpharma Pty Limited Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
SE9904289D0 (sv) * 1999-11-26 1999-11-26 Niklas Arnberg Method and camposition for the treatment of adenovairal ocular infections
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
DE10065710A1 (de) * 2000-12-29 2002-07-04 Bayer Ag Arzneimittel enthaltend ein Polyamin als Wirksubstanz
AUPR412901A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agents for the prevention and treatment of sexually transmitted disease s - II
AUPR412801A0 (en) 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
WO2003080121A1 (en) * 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research Macromolecular compounds as potential anti-inflammatory agents
GB0209022D0 (en) * 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US20080221020A1 (en) * 2002-07-19 2008-09-11 The Regents Of The University Of California Dendrimers as Molecular Translocators
US7001580B2 (en) * 2002-12-31 2006-02-21 3M Innovative Properties Company Emulsions including surface-modified organic molecules
GR1004516B (el) * 2003-02-13 2004-04-06 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) - "Δημοκριτος" Πολυ-λειτουργικα δενδριμερικα και υπερδιακλαδισμενα πολυμερη ως φορεις φαρμακων
KR20050111586A (ko) * 2003-02-13 2005-11-25 내셔널 센터 포 사이언티픽 리서치 데모크리토스 드러그 및 유전자 전달 시스템으로서의 다기능의 덴드리머및 다중결합된 폴리머
US20040180852A1 (en) * 2003-03-10 2004-09-16 Cara-Lynne Schengrund Use of multivalent glycodendrimers to inhibit the activity of human immunodeficiency virus
BRPI0510093B8 (pt) 2004-04-20 2022-12-27 Dendritic Nanotechnologies Inc polímeros dendríticos
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
EP1817325B1 (de) * 2004-09-21 2009-01-21 Lehigh University 6-200 cholansäure(derivat)-einheiten enthaltende sulfatierte molekulare schirme als anti-hiv- und anti-hsv-mittel
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US8790672B2 (en) * 2005-02-22 2014-07-29 Nina M. Lamba-Kohli Generation of antimicrobial surfaces using dendrimer biocides
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP3000460A1 (de) 2005-09-15 2016-03-30 Genzyme Corporation Beutelformulierung für aminpolymere
EP1937284B1 (de) * 2005-10-18 2015-12-02 Starpharma Pty Limited Abgabesystem für eine mikrobizide dendrimer-zusammensetzung
WO2007045010A1 (en) * 2005-10-21 2007-04-26 Starpharma Pty Limited Inhibitory compounds
DE102005056592A1 (de) * 2005-11-25 2007-05-31 Basf Ag Herstellung und Verwendung von hochfunktionellen, hoch-oder hyperverzweigten Polylysinen
NZ569756A (en) 2005-12-12 2011-07-29 Allaccem Inc Methods and systems for preparing antimicrobial films and coatings utilising polycyclic bridged ammonium salts
CN101003607B (zh) * 2006-01-16 2010-09-01 博阳生物科技(上海)有限公司 封闭树状大分子的方法、经封闭的树状大分子及其用途
CN104524596B (zh) * 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US8193248B2 (en) 2006-03-22 2012-06-05 Starpharma Pty Limited Contraceptive composition
EP2016114A2 (de) * 2006-05-05 2009-01-21 Genzyme Corporation Aminkondensationspolymere als phosphatkomplexbildner
AU2007275711A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2066293A2 (de) 2006-09-29 2009-06-10 Genzyme Corporation Amid-dendrimer-zusammensetzungen
WO2008063157A2 (en) * 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A nanoparticle-based anticoagulant
US8163799B2 (en) * 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
JP2010519298A (ja) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
EP2131820A1 (de) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfonpolymerzusammensetzungen
EP2152277A1 (de) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amin-dendrimer-zusammensetzungen
WO2008157372A2 (en) 2007-06-14 2008-12-24 Massachusetts Institute Of Technology Self assembled films for protein and drug delivery applications
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
WO2009078958A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Coated pharmaceutical compositions
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
WO2010021973A2 (en) 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
WO2011036560A2 (en) 2009-09-23 2011-03-31 Novartis Ag Glycoconjugate compositions and methods for treatment of hiv
RS59598B1 (sr) * 2011-05-16 2020-01-31 Starpharma Pty Ltd Postupak lečenja ili profilakse bakterijske vaginoze
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013163234A1 (en) 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
CN105007910B (zh) * 2012-09-13 2019-03-19 星法马有限公司 眼部感染的治疗或预防药物的制造用途
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
EP2987503A1 (de) * 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Verfahren und Reagenzien zur Prävention und/oder Behandlung von Infektionen
US10479868B2 (en) 2014-09-04 2019-11-19 Nano Precision Medical, Inc. Polymeric stabilizing formulations
US12071516B2 (en) 2014-09-04 2024-08-27 Nano Precision Medical, Inc. Polymeric stabilizing formulations
US10154956B2 (en) * 2015-07-28 2018-12-18 Carnegie Mellon University Methods and compounds to suppress viral genome release and packaging
US10702572B2 (en) 2015-07-28 2020-07-07 Carnegie Mellon University Methods and compounds to suppress viral genome release and packaging
WO2017190193A1 (en) * 2016-05-05 2017-11-09 Starpharma Pty Ltd Method of prophylaxis of zika virus infection
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2021002984A1 (en) 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
CN114174276A (zh) * 2019-08-05 2022-03-11 国际商业机器公司 实现增强的抗微生物活性的组合疗法
US11028264B2 (en) 2019-08-05 2021-06-08 International Business Machines Corporation Polylysine polymers with antimicrobial and/or anticancer activity
EP3930730A4 (de) * 2020-04-15 2022-05-11 Starpharma Pty Limited Verfahren zur prophylaxe der infektion mit coronavirus und/oder respiratorischem synzytialvirus
GB202007701D0 (en) 2020-05-22 2020-07-08 Univ Manchester Antiviral polymers
CN114053392B (zh) * 2020-07-30 2024-06-21 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗hpv感染的药物中的应用
CN114053394B (zh) * 2020-07-30 2024-06-21 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
US20220040315A1 (en) 2020-08-09 2022-02-10 Fulu Labs Corporation Nuclease-dendrimer formulations for covid-19 and broad-spectrum antiviral therapy and prophylaxis
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4599400A (en) * 1984-12-18 1986-07-08 The Dow Chemical Company Star/comb-branched polyamide
IL83567A (en) * 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA1341285C (en) 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
EP0339695A3 (de) 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen Verfahren zur Herstellung eines antigenen bzw. immunogenen Konjugats sowie die Verwendung solcher Konjugate
JPH03236366A (ja) * 1989-12-22 1991-10-22 Banyu Pharmaceut Co Ltd グアニジノベンゼン誘導体
US5312837A (en) * 1991-01-29 1994-05-17 Genelabs Technologies, Inc. Method of treating viral infections with aryl macrocyclic compounds
NL9100434A (nl) * 1991-03-11 1992-10-01 Rijksuniversiteit Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan.
WO1993003766A1 (en) 1991-08-13 1993-03-04 Repligen Corporation Multiple antigen peptides for use as hiv vaccines
EP0610431A1 (de) * 1991-11-01 1994-08-17 Smithkline Beecham Corporation HIV Protease Inhibitoren die Guanidin enthalten.
EP0708637B1 (de) * 1993-07-14 2004-01-28 The Regents of the University of California Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält

Also Published As

Publication number Publication date
ATE312866T1 (de) 2005-12-15
NZ287819A (en) 1998-06-26
JP2006070036A (ja) 2006-03-16
AUPM623994A0 (en) 1994-07-07
HK1002899A1 (en) 1998-09-25
JP4589851B2 (ja) 2010-12-01
EP0765357B1 (de) 2005-12-14
DE69534686T2 (de) 2006-09-21
JPH10501568A (ja) 1998-02-10
CN1154123A (zh) 1997-07-09
BR9508031A (pt) 1997-09-16
EP0765357B9 (de) 2006-08-16
EP0765357A4 (de) 1997-07-30
PT765357E (pt) 2006-05-31
EP0765357B8 (de) 2006-03-08
CA2192446A1 (en) 1995-12-21
US6190650B1 (en) 2001-02-20
ES2255060T3 (es) 2006-06-16
DE69534686D1 (de) 2006-01-19
KR100365028B1 (ko) 2003-05-12
CN1134486C (zh) 2004-01-14
EP0765357A1 (de) 1997-04-02
WO1995034595A1 (en) 1995-12-21
CA2192446C (en) 2004-08-31

Similar Documents

Publication Publication Date Title
DK0765357T3 (da) Antivirale dendrimerer
NL300151I2 (nl) Boronzuurester- en boronzuurverbindingen, syntheseen toepassingen.
DK0927217T3 (da) Antiangiogene forbindelser
ATE258205T1 (de) Zusammensetzungen und verfahren für die kontrolle von klebenden verunreinigungen
MX9606421A (es) Dendrimeros antivirales.
HN1997000136A (es) Tetrahidro 6h pirazino (1,2-b)isoquinolin - 14 dionas.
TH9801000281A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801001160A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000186A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000142A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000119A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000117A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000112A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000080A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000226A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000257A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000355A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801003861A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801002894A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801001302A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801001251A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801001240A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000302A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801000755A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH9801001148A (th) สิทธิบัตรยังไม่ประกาศโฆษณา